Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Nov 4;116(5):1054-1060.
doi: 10.1093/jleuko/qiae116.

TIGIT stimulation suppresses autoimmune uveitis by inhibiting Th17 cell infiltration

Kayleigh Peters  1 , Trisha McDonald  1 , Fauziyya Muhammad  2 , Adrien Brady  3 , John Dostal  3 , Darren J Lee  1   2   3
Affiliations

TIGIT stimulation suppresses autoimmune uveitis by inhibiting Th17 cell infiltration

Kayleigh Peters et al. J Leukoc Biol. .

Abstract

T cell immunoglobulin and ITIM domain (TIGIT) is an immune checkpoint molecule that suppresses T cell activation and promotes an immunosuppressive environment to suppress autoimmune diseases. However, the impact of a TIGIT agonist as a treatment for ocular autoimmune disease has not been investigated. We examined TIGIT expression on T helper 17 (Th17) and regulatory T cells (Tregs), the role of TIGIT on experimental autoimmune uveitis and Th17 cells, and the impact of Treg generation following TIGIT stimulation. TIGIT stimulation at the onset of clinical symptoms reduced the severity of uveitis and suppressed infiltration of Th17 cells into the eye. Further, Tregs from mice treated with the TIGIT agonist were capable of suppressing experimental autoimmune uveitis in recipient mice. This report demonstrates that stimulation of TIGIT at onset of disease suppresses symptoms and allows for induction of regulatory immunity that provides resistance to uveitis.

Keywords: TIGIT+ Tregs; autoimmune uveitis; ocular immune privilege; th17 cells.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest statement. None declared.

References

    1. Yu X, Harden K, Gonzalez LC, Francesco M, Chiang E, Irving B, Tom I, Ivelja S, Refino CJ, Clark H, et al. . The surface protein TIGIT suppresses T cell activation by promoting the generation of mature immunoregulatory dendritic cells. Nat Immunol. 2009:10(1):48–57. 10.1038/ni.1674 - DOI - PubMed
    1. Lee DJ. The relationship between TIGIT+ regulatory T cells and autoimmune disease. Int Immunopharmacol. 2020:83:106378. 10.1016/j.intimp.2020.106378 - DOI - PMC - PubMed
    1. Zhao W, Dong Y, Wu C, Ma Y, Jin Y, Ji Y. TIGIT overexpression diminishes the function of CD4 T cells and ameliorates the severity of rheumatoid arthritis in mouse models. Exp Cell Res. 2016:340(1):132–138. 10.1016/j.yexcr.2015.12.002 - DOI - PubMed
    1. Downs-Canner S, Berkey S, Delgoffe GM, Edwards RP, Curiel T, Odunsi K, Bartlett DL, Obermajer N. Suppressive IL-17A(+)foxp3(+) and ex-Th17 IL-17A(neg)Foxp3(+) Treg cells are a source of tumour-associated Treg cells. Nat Commun. 2017:8(1):14649. 10.1038/ncomms14649 - DOI - PMC - PubMed
    1. Dixon KO, Schorer M, Nevin J, Etminan Y, Amoozgar Z, Kondo T, Kurtulus S, Kassam N, Sobel RA, Fukumura D, et al. . Functional anti-TIGIT antibodies regulate development of autoimmunity and antitumor immunity. J Immunol. 2018:200(8):3000–3007. 10.4049/jimmunol.1700407 - DOI - PMC - PubMed

Substances

LinkOut - more resources